Amersham plc
British radiopharmaceutical, medical diagnostics, and life-science company that became part of GE Healthcare after a 2004 acquisition.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Amersham plc was a British healthcare and life-science company whose origins lay in the wartime and postwar processing of radioactive materials at Chilcote House in Little Chalfont, near Amersham, Buckinghamshire. The site began extracting radium from concentrates in 1940 under Walter Patrick Grove. During the following years it produced radium bromide for luminous dials and instruments, before being taken over by the Ministry of Supply in 1946 and developed into a national facility for processing and distributing radium, radon, and artificial radioactive substances for scientific, medical, and industrial use. The operation adopted the name The Radiochemical Centre, Amersham, in 1949. Its remit expanded beyond radium to include materials such as carbon-14, radioactive capsules for cancer treatment, and other radioisotopes. In 1950 it became an outstation of the Atomic Energy Research Establishment at Harwell. By the 1960s, the centre had built an unusually broad catalogue of radiochemical products, used more than one hundred isotopes, exported to dozens of countries, and installed a cyclotron for medical isotope production. A second production site was developed in Cardiff from 1976, supporting the organization’s growing industrial and international footprint. In 1971, following restructuring of the United Kingdom Atomic Energy Authority, The Radiochemical Centre became a limited company. It later changed its name to Amersham International Limited and was privatized in 1982 as Amersham International plc. The transaction was historically significant because it was the first privatization in which the British government sold all of its shares in a company. The government retained a special share for a period, enabling it to veto certain outsourcing arrangements; that share was redeemed in 1988. Amersham subsequently broadened its activities from radiochemicals into in-vitro diagnostics, molecular biology, biotechnology, and other life-science tools. Its diagnostics business was placed into a joint venture with Eastman Kodak in the early 1990s and later passed through Kodak and Johnson & Johnson ownership before becoming part of Ortho Clinical Diagnostics. In 1997, Amersham Life Science was combined with Pharmacia Biotech, creating Amersham Pharmacia Biotech. After Amersham acquired the relevant interest, the business was renamed Amersham Biosciences in 2001. The corporate group also changed shape through a 1997 merger with Norway’s Nycomed, becoming Nycomed Amersham plc. Nycomed Pharma was sold to Nordic Capital in 1999, and the remaining company adopted the shorter name Amersham plc in 2001. Its businesses were generally associated with two broad areas: medical diagnostics, particularly radiopharmaceuticals and imaging-related products, and life sciences, including research reagents, instruments, and biotechnology supplies. General Electric agreed to acquire Amersham in 2004, after which the company was absorbed into GE Healthcare rather than continuing as an independent listed group. The former Amersham businesses became part of GE Healthcare Medical Diagnostics and GE Healthcare Life Sciences. The original Buckinghamshire site remained associated with GE Healthcare for many years, while the Cardiff operation was later consolidated and partly redeveloped. In 2005, the Royal Society of Chemistry designated the former Amersham Laboratories, then known as the Grove Centre under GE, an historic chemical landmark in recognition of its contributions to industrial and medical applications. GE Healthcare Life Sciences was ultimately acquired by Danaher in 2020 and renamed Cytiva, extending the lineage of Amersham’s life-science activities beyond the company’s independent existence.
History
Amersham’s history began at Chilcote House in Little Chalfont, close to Amersham in Buckinghamshire. In 1940 the site was used to extract radium from concentrates under Walter Patrick Grove. Over the next four years, the facility produced more than five hundred kilograms of radium bromide for luminous dials and instruments. In 1946 the Ministry of Supply took control and developed the location as a national centre for processing and distributing radium, radon, and artificial radioactive substances for scientific, medical, and industrial purposes. The site was renamed The Radiochemical Centre, Amersham, in 1949. Its products included radium gas capsules used in cancer treatment and carbon-14, alongside other radiochemical materials. In 1950 the centre became an outstation of the Atomic Energy Research Establishment at Harwell, linking its manufacturing role with the United Kingdom’s nuclear research infrastructure. Expansion during the following decades made it an international supplier of isotope-based products. By the 1960s, the organization had more than one thousand catalogue items, worked with over one hundred isotopes, exported to approximately sixty countries, and had installed a cyclotron intended for medical isotope production. A second production facility was begun in Cardiff in 1976. A restructuring of the United Kingdom Atomic Energy Authority in 1971 turned The Radiochemical Centre into a limited company. The company later became Amersham International Limited and, in 1982, Amersham International plc. Its privatization was a landmark in the Thatcher-era program because the government sold its entire shareholding, rather than retaining an ordinary equity stake. A special share gave the government limited veto rights over outsourcing arrangements until it was redeemed in 1988. During the 1990s, Amersham expanded beyond its original radiochemical base. Its in-vitro diagnostic assay activities were placed into Amerlite Diagnostics Ltd, a joint venture with Eastman Kodak. Kodak subsequently acquired the business outright and renamed it Kodak Clinical Diagnostics. Johnson & Johnson later acquired that business, which became Johnson & Johnson Clinical Diagnostics and ultimately Ortho Clinical Diagnostics. Amersham also developed a substantial life-science division. In 1997, Amersham Life Science was combined with Sweden’s Pharmacia Biotech, then owned by Pharmacia & Upjohn, producing Amersham Pharmacia Biotech. After Pharmacia & Upjohn disposed of its interest, Amersham took full control and the subsidiary was renamed Amersham Biosciences in 2001. The wider company merged with Norwegian healthcare group Nycomed in 1997 and became Nycomed Amersham plc. Nycomed Pharma was sold to Nordic Capital in 1999, and the remaining organization returned to the Amersham plc name in 2001. The company’s later portfolio combined medical diagnostics with life-science research products. Radiopharmaceuticals and other isotope-based offerings served diagnostic and therapeutic nuclear medicine, while the life-science business supplied research materials and technologies for biotechnology and laboratory work. This combination made Amersham a specialist healthcare group with activities spanning clinical applications and research markets. General Electric acquired Amersham in 2004 and integrated the company into GE Healthcare. The former businesses were organized principally as GE Healthcare Medical Diagnostics and GE Healthcare Life Sciences. GE Healthcare retained a UK presence near Amersham, and the former Amersham site remained associated with the business until later consolidation. In 2005, the Royal Society of Chemistry designated the former Amersham Laboratories, then known as the Grove Centre under GE, an historic chemical landmark for its achievements in industrial and medical applications over six decades. The corporate succession continued after Amersham disappeared as an independent company. Part of the Cardiff site was sold for redevelopment in 2018 as operations were consolidated. In 2020, Danaher acquired GE Healthcare Life Sciences and renamed the business Cytiva. This transaction transferred a significant part of Amersham’s life-science legacy into a new corporate owner, while the Amersham plc name remained a historical reference rather than an active independent brand.
- 2020
GE Healthcare Life Sciences becomes Cytiva
[1]Danaher acquires GE Healthcare Life Sciences and renames the business Cytiva.
- 2018
Part of Cardiff site sold for redevelopment
[1]A portion of the former Cardiff facility is sold as operations are consolidated into a smaller area.
- 2005
Historic chemical landmark designation
[1]The Royal Society of Chemistry recognizes the former Amersham Laboratories for industrial and medical achievements.
- 2004
Acquired by General Electric
[1]GE acquires Amersham and integrates it into GE Healthcare.
- 2001
Company becomes Amersham plc
[1]Nycomed Amersham plc adopts the shorter Amersham plc name, while the life-science subsidiary becomes Amersham Biosciences.
- 1999
Nycomed Pharma is sold
[1]The Nycomed Pharma subsidiary is sold to Nordic Capital, narrowing the group’s post-merger structure.
- 1997
Merger with Nycomed
[1]Amersham combines with Nycomed to form Nycomed Amersham plc.
- 1997
Amersham Pharmacia Biotech is formed
[1]Amersham Life Science and Pharmacia Biotech are combined into a new life-science business.
- 1988
Government special share is redeemed
[1]The special share retained at privatization, which provided limited veto rights over outsourcing, is redeemed.
- 1982
Privatized as Amersham International plc
[1]The company becomes the first enterprise fully privatized by the British government through the sale of all its shares.
Products and positioning
A science-led healthcare and life-science company built around radioactive materials, nuclear medicine, diagnostics, and biotechnology research tools. Amersham combined industrial-scale isotope expertise with products for clinical diagnosis, therapy, laboratory research, and biopharmaceutical development.
Nuclear medicine
Radiopharmaceuticals
Amersham’s core healthcare activity involved radioactive medicinal products used in diagnostic and therapeutic nuclear medicine. The historical portfolio included radium-based treatment materials and later generations of isotope-based products intended to support medical imaging or targeted treatment. These products reflected the company’s distinctive position at the intersection of nuclear technology, pharmaceutical manufacturing, and clinical diagnostics.
Radiochemistry · 1949
Radiochemicals and medical isotopes
The Radiochemical Centre developed a broad catalogue of radiochemicals using many different isotopes for medical, industrial, and scientific applications. Products included carbon-14 and other labeled materials, as well as radioactive substances supplied for laboratory research and nuclear-medicine use. The portfolio grew from the original radium-processing operation into an internationally exported range of isotope-based materials.
Medical diagnostics
In-vitro diagnostic assays
Amersham developed an in-vitro diagnostic assay business during its diversification beyond radiochemistry. In the early 1990s, this activity was transferred to Amerlite Diagnostics, a joint venture with Eastman Kodak. The business later moved to Kodak, Johnson & Johnson, and ultimately Ortho Clinical Diagnostics, so it no longer operated under the Amersham name.
Life-science research
Amersham Life Science products
Amersham Life Science represented the company’s expansion into research and biotechnology products. Its activities were combined with Pharmacia Biotech in 1997 and later operated as Amersham Biosciences. The business formed part of the life-science succession that passed to GE Healthcare and, in 2020, to Danaher’s Cytiva organization.
Brand decisions
2004
Accept acquisition by General ElectricM&ABackground
Amersham had developed a portfolio spanning medical diagnostics, radiopharmaceuticals, and life-science research, making it a strategic fit for GE’s healthcare expansion.
Action taken
General Electric acquired Amersham and incorporated its operations into GE Healthcare.
Aftermath
Amersham ceased to operate as an independent listed company. Its former divisions became associated with GE Healthcare Medical Diagnostics and GE Healthcare Life Sciences.
1997
Merge with NycomedM&ABackground
Amersham pursued a broader healthcare structure through a combination with Norway-based Nycomed.
Action taken
The companies merged to form Nycomed Amersham plc.
Aftermath
Nycomed Pharma was later sold to Nordic Capital in 1999, and the remaining company returned to the Amersham name in 2001.
1997
Combine Amersham Life Science with Pharmacia BiotechM&ABackground
The company sought to expand and consolidate its biotechnology and laboratory-research activities.
Action taken
Amersham Life Science was fused with Pharmacia Biotech, creating Amersham Pharmacia Biotech.
Aftermath
After Pharmacia & Upjohn sold its interest, the business became Amersham Biosciences in 2001 and was later absorbed into GE Healthcare Life Sciences.
1982
Proceed with full privatizationStrategyBackground
The British government decided to sell its entire shareholding in Amersham International, making the transaction an early landmark of the UK privatization program.
Action taken
Amersham International was floated as a public company, while the government temporarily retained a special share with limited veto rights over outsourcing arrangements.
Aftermath
The transaction established Amersham as an independent listed healthcare and life-science company. The special share was later redeemed in 1988.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/amersham-plc · Editorial policy · How profiles are compiled